4-(4-Hydroxyphenyl)salicylaldoxime | 1014625-83-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-Hydroxyphenyl)salicylaldoxime
• 英文别名: 2-[(E)-hydroxyiminomethyl]-5-(4-hydroxyphenyl)phenol
• CAS: 1014625-83-2
• 化学式: C₁₃H₁₁NO₃
• 分子量: 229.235
• InChiKey: SFOYMCBJEFPROT-RIYZIHGNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  73
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(4-hydroxyphenyl)salicylaldehyde 在 盐酸羟胺 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以69%的产率得到4-(4-Hydroxyphenyl)salicylaldoxime
  参考文献：
  名称：

  Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor β

  摘要：

  Salicylaldoximes possess a hydrogen-bonded pseudocyclic A' ring in place of the typical phenolic A ring that is characteristic of most estrogen receptor (ER) ligands. Monoaryl-substituted salicylaldoximes were obtained by replacing the phenol moiety (ring A) of the ER beta pharmacophore with the pseudocycle A' ring, which has previously been shown to behave as a bioequivalent of phenols in nonselective ER ligands. In this series, small substituents (CH(3), CN, Cl) were introduced into the central phenyl scaffold. An efficient sequential halogen-selective double cross-coupling reaction was developed for the synthesis of the methylsubstituted ER ligand. The measured ER beta affinity proved to be very sensitive to the effect of central core substituents. The binding affinities of the compounds herein reported were in good agreement with the results of computational docking analysis. The chloro-substituted derivative showed the highest beta affinity and selectivity, and it also proved to be an ER beta partial agonist with an EC(50) of 11 nM.

  DOI：

  10.1021/jm701396g

文献信息

• [EN] ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS<br/>[FR] AGONISTES DU RÉCEPTEUR BÊTA DES OESTROGÈNES (ERβ) POUR LE TRAITEMENT D'ÉTATS FIBROTIQUES
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2020160225A1

  公开（公告）日：2020-08-06

  Disclosed are method of treating fibrotic conditions using estrogen receptor β (ERβ) agonists.
• [EN] METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERΒ) AGONISTS<br/>[FR] MÉTHODES DE MODULATION DE L'ACTIVATION DES LYMPHOCYTES T À L'AIDE D'AGONISTES DU RÉCEPTEUR BÊTA DES ŒSTROGÈNES (ERΒ)
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2021183760A1

  公开（公告）日：2021-09-16

  Disclosed are method of modulating immune response in a subject using ERβ agonists. The ERβ agonists can selectively inhibit the activation and/or proliferation of T-cells, reducing circulating T-cell levels in a subject without significantly affecting circulating levels of neutrophils, monocytes, or B-cells. As a result, the ERβ agonists can be used in therapeutic and/or prophylactic applications, including to treat or prevent chronic heart failure (CHF) in a subject post-myocardial infarction (MI) and to treat or prevent graft-versus-host disease (GVHD), multiple sclerosis (MS), and/or experimental autoimmune encephalomyelitis (EAE) in a subject.
• Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor β
  作者：Filippo Minutolo、Rosalba Bellini、Simone Bertini、Isabella Carboni、Annalina Lapucci、Letizia Pistolesi、Giovanni Prota、Simona Rapposelli、Francesca Solati、Tiziano Tuccinardi、Adriano Martinelli、Fabio Stossi、Kathryn E. Carlson、Benita S. Katzenellenbogen、John A. Katzenellenbogen、Marco Macchia

  DOI：10.1021/jm701396g

  日期：2008.3.13

  Salicylaldoximes possess a hydrogen-bonded pseudocyclic A' ring in place of the typical phenolic A ring that is characteristic of most estrogen receptor (ER) ligands. Monoaryl-substituted salicylaldoximes were obtained by replacing the phenol moiety (ring A) of the ER beta pharmacophore with the pseudocycle A' ring, which has previously been shown to behave as a bioequivalent of phenols in nonselective ER ligands. In this series, small substituents (CH(3), CN, Cl) were introduced into the central phenyl scaffold. An efficient sequential halogen-selective double cross-coupling reaction was developed for the synthesis of the methylsubstituted ER ligand. The measured ER beta affinity proved to be very sensitive to the effect of central core substituents. The binding affinities of the compounds herein reported were in good agreement with the results of computational docking analysis. The chloro-substituted derivative showed the highest beta affinity and selectivity, and it also proved to be an ER beta partial agonist with an EC(50) of 11 nM.